

Commonly Prescribed Hepatitis C Medications

Single-Tablet Regimens

Epclusa
(sofosbuvir + velpatasvir)



Harvoni
(sofosbuvir + ledipasvir)



Mavyret
(glecaprevir/pibrentasvir)



Viekira Pak
(ombitasvir/paritaprevir/ritonavir + dasabuvir)



Vosevi
(sofosbuvir/velpatasvir/voxilaprevir)



Zepatier
(elbasvir + grazoprevir)



Nucleoside Analogs

Copegus
(ribavirin)



Moderiba
(ribavirin)



Rebetol
(ribavirin)



Ribasphere
(ribavirin)




Virazole
(ribavirin)



Nucleoside and Nucleotide NS5B Polymerase Inhibitors

Sovaldi
(sofosbuvir (GS-7977))



NS5A Inhibitors

Daklinza
(daclatasvir (BMS-790052))




Discontinued

Incivek
(telaprevir)




Olysio
(simeprevir (TMC435))



PegIntron
(peginterferon alfa-2b)



Pegasys
(peginterferon alfa-2b)





Technivie
(ombitasvir/paritaprevir/ritonavir)



Victrelis
(boceprevir)



Hepatitis C Medication Targets



CCF ©2014

Community Resource Initiative (CRI) is an independent, nonprofit, community-based organization dedicated to ending the HIV epidemic through **Research, Prevention, Access to Treatment, and Impact.**



Since 1989, CRI has produced critical data that has contributed to the FDA approval of nearly all of the currently available HIV treatments and forever changed the direction of HIV/AIDS treatment around the world.

Through its management of the Massachusetts Infectious Disease Drug Assistance Program (IDDAP)¹, CRI provides access to medications and health insurance coverage to Massachusetts residents living with HIV or taking preventive treatment. Through its continued outreach efforts, CRI provides the latest treatment information to people living with HIV, hepatitis C, and other infectious diseases.

About the medication chart:

CRI produces the medication chart with funding from the Bureau of Infectious Disease, Office of HIV/AIDS, Massachusetts Department of Public Health. It displays or names all formulations of each HIV or HCV medication currently or recently available. Medications on the chart are listed in the following manner:

- Grouped by class
- Commercial brand name in **bold**
- Formal clinical name (in parentheses), which may also be the name used in studies/trials before a medication received FDA approval and became available to the public

CRI updates the chart as needed, with the date of each version noted. Copies are available upon request. For more information or to order copies of the chart, please contact CRI Development and Communications at info@crihealth.org or 617.502.1726.

Visit our website at www.crihealth.org

¹ A program of the Massachusetts Department of Public Health.

Hepatitis C Medication Chart

Current as of 06/24

617.502.1700 | www.crihealth.org